European Medicines Agency publishes update on pioglitazone-containing medicines review
23 June 2011
The European Medicines Agency (EMA) has today published an update regarding the ongoing benefit/risk review of pioglitazone-containing medicines. Data from pharmacoepidemiological studies, non-clinical and clinical data and post-marketing reports on pioglitazone-containing medicines and the occurrence of bladder cancer are currently being evaluated to assess their impact on the balance of benefits and risks of these medicines. No regulatory action is proposed at this time. The Committee for Human Medicinal Products (CHMP) will finalise its review in July and make recommendations on the future use of these medicines.
See EMA Press Release for further information.